Grand Challenges in Pharmacoeconomics and Health Outcomes by Dubois, Dominique J.
www.frontiersin.org  June 2010  | Volume 1  |  Article 7  |  1
OpiniOn Article
published: 23 June 2010
doi: 10.3389/fphar.2010.00007
Grand challenges in pharmacoeconomics and health 
outcomes
Dominique J. Dubois*
Pharmed, Université Libre de Bruxelles (ULB), Brussels, Belgium
*Correspondence: dominique@pvsconsultancy.com
Pharmacoeconomics and health outcomes 
research are playing an increasingly impor-
tant role in informing clinical development 
and market access decisions of new innova-
tive medicines. Both disciplines are dealing 
with the evaluation of the costs and out-
comes of healthcare interventions and can 
be considered as two branches of the same 
“value for money” tree.
Pharmacoeconomics is the part of health 
economics that focuses on the economic 
evaluation of pharmaceuticals. Health 
outcomes research, and patient-reported 
outcomes (PRO) in particular, aim at 
understanding patient value in terms of 
impact of disease and its treatment on 
physical functioning and psychosocial well-
being, known also as “health-related quality 
of life” (HRQL). PRO’s are usually measured 
by self-reported questionnaires, thereby 
reflecting the patient’s own viewpoint on 
the value of a new medicinal product. In 
many clinical development studies, HRQL 
is nowadays routinely measured to help 
establish the product’s value for purposes 
of pricing and reimbursement.
Despite this growing interest, both dis-
ciplines face numerous challenges going 
forward. The key question remains to what 
extent pharmacoeconomic evaluations and 
outcomes research are delivering better 
 value-based  decisions.
Today, economic evaluation of new medi-
cines is mandatory in many countries, so the 
question is no longer whether or not phar-
macoeconomics is here to stay. The train 
has left the station. But challenges remain, 
mainly related to methodological issues.
In contrast, I believe the jury is still out 
on HRQL and PRO research. A recent sur-
vey suggests that although clinicians rec-
ognize the importance of PRO’s, limited 
experience and information is a barrier to 
the use of quality of life assessment in their 
own clinical practice. Interestingly, a large 
majority acknowledged that they would use 
more expensive medicines if these could 
improve HRQL (Bossola et al., 2010).
Shared challengeS and concernS
As is the case for pharmacoeconomics, there 
is a huge need for training and education 
on what HRQL is all about, how to meas-
ure it, and – above all – how to analyze and 
interpret results. The biggest challenge is 
with the interpretation and effective com-
munication of the clinical meaningfulness 
of HRQL data. Indeed, the question that 
many clinicians and payers are asking about 
PRO’s is “What do these numbers and scores 
really mean?”
Another major challenging area of 
interest for both pharmacoeconomics and 
outcomes research is the role of Quality 
Adjusted Life Years (QALYs) in economic 
evaluation. The QALY concept used in cost-
utility analyses is increasingly subject of 
methodological debate. The main concern 
is that different methods for valuing health 
state preferences may yield different results 
(Drummond et al., 2009).
A related issue is the respective role 
of preference-based utilities versus other 
PRO’s to facilitate market access. The use 
of cost-utility analysis is the preferred form 
of economic evaluation in several countries 
to inform market access decisions. Other 
countries are in favor of disease-specific 
outcomes. The challenge is to convince the 
decision makers that there is more to HRQL 
than health utilities alone. Therefore, HRQL 
PRO’s should be given a more prominent 
role in support of value-based pricing and 
reimbursement.
The predominant role of generic meas-
ures to estimate utilities is also reason for 
concern. Advances in methods for mapping 
disease-specific quality of life measures 
onto generic preference-based measures 
open new prospects for better capturing 
clinically meaningful changes in response 
to treatment.
Pharmacoeconomic challengeS
This is a challenging time for the pharma-
ceutical industry, with blockbuster drugs 
going off-patent, generics competition and 
a pressing need for innovative medicines, 
associated with rising drug development 
costs. The role for pharmacoeconomics 
could not be more timely.
Early cost-effectiveness evaluations are 
likely to become a key component in defin-
ing no go areas for clinical development. 
Likewise, pharmacoeconomic evaluations 
will be able to assist in the development 
of performance based pricing and reim-
bursement agreements. Personalized drug 
treatments are also a fast growing area of 
interest. Genetic tests that allow to predict 
responders to treatment offer substantial 
opportunities for efficient use of expensive 
new therapies.
A major methodological challenge is 
the limited generalizability of the results 
of randomized controlled trials (RCT). On 
the one hand, the RCT is the gold standard 
design for establishing safety and efficacy, 
with the highest degree of internal valid-
ity. However, findings from RCT’s may 
have poor external validity for the wider 
patient population in daily clinical practice. 
Typical extrapolation issues of RCT designs 
include inadequate sample size, restrictive 
patient selection (patient characteristics, 
co-  morbidities, disease severity), inap-
propriate comparator, short time horizon, 
protocol-driven resource use, artificially 
enhanced compliance, and inappropriate 
consequence measures (Simoens, 2009).
Healthcare resource utilization data can 
be collected alongside RCT’s (Drummond 
and Davies, 1991), but this is not always 
feasible. Economic evaluation models can 
be used when the relevant clinical trials are 
not possible for ethical or logistical rea-
sons. Modeling allows data from different 
available sources to be combined (Nuijten, 
1998). Further improvements in evaluat-
ing health- and economic outcomes in 
daily practice are expected from pragmatic 
trials with a minimum of exclusion crite-
ria, purpose build databases, registries and 
qualitative research. There will always be a 
trade-off between the evidence obtained Frontiers in Pharmacology | Pharmaceutical Medicine and Outcomes Research  June 2010  | Volume 1  |  Article 7  |  2
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recently been recommended by the FDA 
to demonstrate effect of treatment on 
PRO endpoints (Patrick et al., 2007). 
Increased cumulative distribution curve 
reporting will improve the interpretation 
of PRO data as they show the full pat-
tern of response over time and therefore 
enable the entire distribution of responses 
to be compared between treatment groups 
(Dubois et al., 2010).
The above challenges are exemplative 
but by no means limitative. There are many 
more issues of interest to be considered. 
For example, what is the experience with 
newer psychometric methods, such as item 
response theory and computerized adaptive 
testing? Do they enable HRQL assessment 
in daily practice? What is the incremental 
value of probabilistic versus deterministic 
sensitivity analyses alone? Does it lead to 
different decisions?
Sharing these current and emerging issues 
and opportunities will be a key succes factor 
for developing high quality solutions for the 
grand challenges ahead. To that end, Frontiers 
in Pharmacoeconomics and Health Outcomes 
welcomes a broad range of contributions that 
may help the field going forward.
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in controlled conditions and data com-
ing from other sources of information, 
but scientific and clinical judgment on the 
merits of all the available evidence should 




Some PRO’s, such as pain and other symp-
toms severity, are used routinely as primary 
endpoints in clinical trials to demonstrate 
the patient benefit of new medicines, and are 
well accepted. However, HRQL PRO’s are still 
perceived by some as a subjective measure of 
secondary importance, despite an increas-
ing body of evidence of a significant growth 
in PRO research and applications. Further 
acceptance of PRO’s is substantiated by the 
final FDA PRO guidance and the European 
Medicines Agency reflection paper on the 
regulatory guidance for the use of HRQL 
measures in the evaluation of medicinal 
products (European Medicines Agency/
Committee for Medicinal Products for 
Human Use/Efficacy Working Party, 2006; 
Food and Drug Administration/Center for 
Drug Evaluation and Research, 2009).
Another challenge concerns the use of 
quality of life assessments during the whole 
lifecycle of a new treatment, and not only 
during pre-registration clinical develop-
ment studies. As a unique measure of the 
patient perspective, PRO assessment may 
provide a useful tool for informing daily 
medical practice.
A third major challenge is associated 
with the difficulty in understanding 
and communicating the clinical mean-
ingfulness of HRQL data. Cumulative 
distribution curves rather than mini-
mal important difference criteria have 